Table 4.
Baseline demographic and disease characteristics
| Characteristic | Total (n = 860) |
|---|---|
| Age, years | |
| Mean (SD) | 65.3 (10.8) |
| Sex, n (%) | |
| Male | 576 (67.0) |
| Female | 284 (33.0) |
| Race, n (%) | |
| White | 621 (72.2) |
| Black or African American | 116 (13.5) |
| American Indian or Alaska Native | 29 (3.4) |
| Asian | 20 (2.3) |
| Other | 70 (8.1) |
| Missing | 2 (0.2) |
| Region,an (%) | |
| North America | 373 (43.4) |
| Europe | 376 (43.7) |
| South Africa | 111 (12.9) |
| Body mass index, kg/m2 | |
| Mean (SD) | 32.0 (6.3) |
| Blood pressure, mmHg | |
| Systolic | 136.4 (16.6) |
| Diastolic | 75.4 (10.3) |
| eGFR, mL/min/1.73 m2 | |
| Mean (SD) | 47.8 (17.9) |
| eGFR categories, mL/min/1.73 m2, n (%) | |
| <30 | 100 (11.6) |
| 30 to <60 | 581 (67.6) |
| 60 to <90 | 149 (17.3) |
| ≥90 | 30 (3.5) |
| NT-proBNP, pg/mL | |
| Median (range) | 188 (25–46025) |
| Serum urate, mg/dL | |
| Median (range) | 7.7 (5.5–13.5) |
| UACR, mg/g | |
| Median (range) | 246 (10–5579) |
| HbA1c, % | |
| Mean (SD) | 7.5 (1.8) |
| Comorbidity, n (%) | |
| Diabetes mellitus | 706 (82.1) |
| Kidney disease aetiology, n (%) | |
| Diabetic nephropathy | 568 (66.0) |
| Ischaemic/hypertensive nephropathy | 156 (18.1) |
| Chronic glomerulonephritis | 25 (2.9) |
| Other/unknown | 111 (12.9) |
| SGLT2 inhibitor, n (%) | 84 (9.8) |
a
Europe: Czech Republic, France, Hungary, Israel, Italy, Poland, Romania, Slovakia and Spain; North America: USA and Mexico; South Africa: South Africa. Baseline data presented in the table are extracted from the study database on 16 March 2021 while the trial was ongoing and before database lock. HbA1c, glycated haemoglobin; n, number of patients.